Scarica l'app Stockscreener
7.02
3.17%
-0.23
Dopo l'orario di chiusura:
6.90
-0.12
-1.71%
Precedente Chiudi:
$7.25
Aprire:
$7
Volume 24 ore:
9,997
Relative Volume:
0.05
Capitalizzazione di mercato:
$3.73M
Reddito:
-
Utile/perdita netta:
$-13.03M
Rapporto P/E:
-0.0566
EPS:
-124.0371
Flusso di cassa netto:
$-6.53M
1 W Prestazione:
-2.36%
1M Prestazione:
+6.20%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$6.7506
$7.30
Intervallo di 1 settimana:
$6.0501
$8.33
Portata 52W:
$4.3201
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Nome
Decoy Therapeutics Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
7.02 | 3.86M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
DCOYDecoy Therapeutics Inc Latest SEC Filings - Finviz
DCOY Q3 2024 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclineRevenue Growth Report - dars.gov.et
Decoy stock rises after announcing up to $21 million private placement financing - MSN
Decoy Therapeutics Inc. Financial Disclosures & Filings - TradingView
Crude Oil Gains 2%; Comcast Shares Spike Higher - Sahm
Market Movers | Winners: TRNR, DCOY, ATLN | Losers: BJDX, EVMN, CELZ - Trefis
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Decoy Therapeutics secures $3.5M PIPE financing; shares surge - MSN
User - The Chronicle-Journal
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally? - Asianet Newsable
Trending Stocks Today | Universe Pharmaceuticals Soars 333.17% - Moomoo
DCOY Stock Explodes Higher As Volatile Biotech Trading Heats Up - StocksToTrade
Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing - Benzinga
Decoy Therapeutics Secures Up to $21 Million PIPE Financing to Advance Multi-Antiviral Clinical Trials - Minichart
DCOY Stock Whipsaws As Traders Eye Volatile Setup - timothysykes.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Morning Market Movers: UPC, DCOY, CMSA, LRMR See Big Swings - RTTNews
Decoy Therapeutics Secures PIPE Financing to Advance Trials - TipRanks
Decoy Therapeutics Raises $3.5 Million in Private Placement at $5.91, Adds Milestone Warrants - TradingView
Decoy Therapeutics (NASDAQ: DCOY) lines up $21M milestone-based PIPE funding - Stock Titan
$Decoy Therapeutics (DCOY.US)$ - Moomoo
Decoy Therapeutics Inc. Actuals & Estimates (FWB:FP11) - TradingView
Decoy Therapeutics Inc. Actuals & Estimates (BOATS:DCOY) - TradingView
Decoy Therapeutics secures $3.5M financing with investor By Investing.com - Investing.com Australia
DECOY THERAPEUTICS, INC. ANNOUNCES UP TO $21 MILLION PRIVATE PLACEMENT FINANCING - Moomoo
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing - Lake Geneva News
Decoy Therapeutics Inc. Actuals & Estimates (GETTEX:FP11) - TradingView
Decoy Therapeutics Inc. Actuals & Estimates (MUN:FP11) - TradingView
Decoy Therapeutics Inc. Actuals & Estimates (NASDAQ:DCOY) - TradingView
[EFFECT] Decoy Therapeutics Inc. SEC Filing - Stock Titan
Decoy Therapeutics (DCOY) Stock Forum and Discussion - Moomoo
Decoy Therapeutics (NASDAQ: DCOY) files S-1 for 808,000-share equity line resale - Stock Titan
Decoy Therapeutics: David Arthur Completing His Service on the Board >DCOY - Moomoo
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London - Morningstar
[RW] Decoy Therapeutics Inc. SEC Filing - Stock Titan
DCOY SEC FilingsDECOY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
DCOY Q3 2024 Earnings: Narrower-Than-Expected Losses Mask Pipeline UncertaintyRevenue Report - dars.gov.et
DCOY | Decoy Therapeutics Inc. Common Executive Compensation - Quiver Quantitative
Decoy Therapeutics (DCOY) details 2026 director, pay and auditor votes - Stock Titan
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Offset Investor ConcernsTrough Earnings Signal - dars.gov.et
Decoy Therapeutics nominates Patricia Gauthier to board - Investing.com UK
Decoy Therapeutics nominates Patricia Gauthier to board By Investing.com - Investing.com South Africa
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PR Newswire
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker - Proactive Investors
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Ca - GuruFocus
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics - Proactive Investors
hVIVO to support Decoy Therapeutics respiratory antiviral development - Vox Markets
hVIVO signs consultancy deal with Decoy Therapeutics By Investing.com - Investing.com Canada
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic - Financial Times
Decoy Therapeutics Inc Azioni (DCOY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Decoy Therapeutics Inc Azioni (DCOY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):